Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Liabilities and Shareholders Equity of $53000.0 for Q4 2025, up 657.14% sequentially from $7000.0 in Q3 2025, and up 96.3% YoY from $27000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $53000.0 in Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 96.3% year-over-year to $53000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $183000.0 (down 67.26% YoY) and the FY2025 annual result came in at $53000.0, up 96.3% from the prior year.
- Liabilities and Shareholders Equity improved to $53000.0 in Q4 2025 per RAPH's latest filing, from $7000.0 in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $422000.0 in Q4 2021 and troughed at $7000.0 in Q3 2025.
- A 5-year average of $164833.3 and a median of $124500.0 in 2022 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity jumped 233.06% in 2023, then plunged 88.7% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $422000.0 in 2021, then slipped by 21.09% to $333000.0 in 2022, then retreated by 28.23% to $239000.0 in 2023, then slumped by 88.7% to $27000.0 in 2024, then jumped by 96.3% to $53000.0 in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $53000.0, $7000.0, and $30000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 128,000.00 |
| Mar 31, 2024 | 353,000.00 |
| Dec 31, 2023 | 239,000.00 |
| Sep 30, 2023 | 403,000.00 |
| Jun 30, 2023 | 119,000.00 |
| Mar 31, 2023 | 150,000.00 |
| Dec 31, 2022 | 333,000.00 |
| Sep 30, 2022 | 121,000.00 |
| Jun 30, 2022 | 196,000.00 |
| Mar 31, 2022 | 180,000.00 |
| Dec 31, 2021 | 422,000.00 |
| Sep 30, 2021 | 62,000.00 |
| Dec 31, 2020 | 323,000.00 |